Background. During the period 1992-1993, the prevalence of hepatitis C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.36%, but contemporary data on the prevalence of antibody to HCV and the prevalence of HCV RNA are lacking.
cinoma and has recently been implicated in the pathogenesis of non-Hodgkin's lymphoma [1, 2] . More than 170 million people worldwide are positive for antibodies to HCV (anti-HCV), with prevalences of 1%-2% in most populations, although prevalences are occasionally much higher because of instances of iatrogenic infection. In the United States, prevalence is 1.6% in the general population, with the highest prevalence among men and those 40-49 years of age [3] . In US blood donors, prevalence was estimated at 0.36% in the early 1990s, again with the highest prevalence in males and middle-aged donors [4] . One study showed a significant decrease in HCV prevalence among first-time US blood donors from 0.63% in 1991 to 0.40% in 1996, whereas another showed an overall decrease in HCV Downloaded from https://academic.oup.com/jid/article-abstract/202/4/576/2192440 by guest on 08 December 2018 prevalence but an increase among men 50-59 years of age [5, 6] . The incidence among repeat blood donors is low, and since the institution of nucleic acid testing (NAT) for HCV RNA in 1999, which allowed the discovery and quarantine of early antibody-negative "window period" blood units, the residual risk of HCV infection has been estimated to be 1 in 1.8 million blood units transfused [7] .
However, recent data on HCV prevalence and risk factors among a large sample of US blood donors are lacking. Such data are important to understand the burden of infection in different donor subgroups and to predict future prevalence for public health purposes. From an epidemiologic standpoint, it has been postulated that HCV infection in the United States demonstrates a birth cohort effect because of an epidemic of transmission by injection drug use in the 1960s and 1970s [4] . If such an effect could be proven by showing a reduced prevalence in more contemporary data, it would have important implications for modeling the future burden of HCV infection in the United States and the health care impact of HCV-related disease outcomes. Current parallel testing of blood donors for anti-HCV and HCV RNA also allows the investigation of the determinants of presumptively resolved HCV infection as manifested by anti-HCV-positive but HCV RNA-negative status.
We therefore performed a large, cross-sectional prevalence study of HCV prevalence among blood donors at a research network of 6 blood centers throughout the United States. Data were compared with those from an earlier published study from a similar US blood center network [4] , and a separate analysis of the determinants of HCV RNA-positive or HCV RNAnegative status was undertaken.
METHODS
Study population and design. This was a cross-sectional seroprevalence study conducted among blood donors at 6 US blood centers from January 2006 through September 2007. The blood centers participated in the Retrovirus Epidemiology Donor Study II and included American Red Cross Blood Services, New England (Vermont, New Hampshire, Maine and Massachusetts) and Southern (Georgia) regions, the Institute for Transfusion Medicine (Pennsylvania), the Hoxworth Blood Center (Ohio), the Blood Center of Wisconsin (Wisconsin), and Blood Centers of the Pacific (California). Computerized data on all blood donations during the study period was forwarded to the coordinating center and merged into a central research database. Each blood donor was represented only once in the data presented here; the donor was considered to be positive if any donation during the study period had positive test results. First-time and repeat donors were defined as those who had or did not have, respectively, a record of previous donation at that center. Body mass index (BMI), calculated as weight in kilograms divided by the square of height in meters, was categorized as normal (!25), overweight (25-29.99 ), or obese (у30). All anti-HCV-positive donors were notified and excluded from future donation according to blood center operational protocols. Data collection was performed under protocols approved by institutional review boards at the 6 participating blood centers.
HCV testing. For the prevalence analysis, HCV infection was defined as the presence of anti-HCV (positive enzymelinked immunosorbent assay [EIA] result followed by a positive recombinant immunoblot result). For the analysis of chronic versus resolved HCV infection, the results from parallel NAT were used to sort anti-HCV-positive subjects into persistently viremic (HCV RNA-positive) and presumptively resolved or resolving (HCV RNA-negative) HCV infections. All laboratory testing was done using US Food and Drug Administrationlicensed assays and under strict standard operating procedures at the blood center laboratories. Anti-HCV was measured with third-generation EIAs; recombinant immunoblot confirmation was done either on all EIA-positive samples (5 centers) or on EIA-positive samples that were NAT negative (1 center), and this had no effect on proportions of confirmed anti-HCV between centers. NAT was done with either transcription-mediated amplification (Genprobe/Novartis; pools of 16) or polymerase chain reaction (Roche Laboratories; pools of 24) techniques.
Statistical analysis. We calculated overall and subgroupspecific anti-HCV and HCV RNA prevalences with 95% confidence intervals (CIs) using the Clopper-Pearson method [8] . Distributions of BMI were compared between HCV status groups using analysis of variance (ANOVA). Three separate multivariable logistic regression models were constructed and used to calculate adjusted odds ratios (aORs) and 95% CIs. In the first, the prevalence analysis included all HCV-screened donors and tested associations between anti-HCV positivity and donor characteristics, irrespective of RNA status. A second prevalence model examining gravidity was similar to the former model but was restricted to female subjects only. In the third model, the analysis of resolved versus chronic HCV infection included anti-HCVpositive individuals only and tested associations of HCV RNAnegative status with various donor characteristics. We used a backward-elimination strategy in constructing each multivariable model. All variables were included in the initial model; those variables without associations ( ) were then excluded from P 1 .10 the final model unless forced in because of biological plausibility or previously published findings.
RESULTS
We reviewed 959,281 donors, of whom 695 (72 per 100,000) had evidence of HCV infection, including 516 (74%) with both anti-HCV and HCV RNA positivity and 179 (26%) with anti-HCV positivity only. Subgroup-specific prevalence and aORs are presented in Table 1 . Anti-HCV prevalence was much higher among first-time donors than it was among repeat donors and was higher among male donors than among female donors. Age-specific prevalence increased to a maximum in the 40-49 and 50-59-year-old age groups and decreased thereafter. Prevalence was lower in 2006-2007 than it was in 1992-1993 in all age and sex groups ( Figure 1 ) [4] , and peak prevalence shifted to older age groups. Prevalence was highest among blacks, was similar in non-Hispanic whites and Hispanics, and was lowest among Asians. In the multivariable logistic regression model for anti-HCV prevalence (Table 1) , we found significant, independent associations between anti-HCV positivity and middle age, male sex, and black versus non-Hispanic white race/ethnicity. Donors with Asian race/ethnicity were significantly less likely to be anti-HCV positive. Significant associations were also seen with high school or lower education, previous blood transfusion, and blood center, and an inverse association was seen with BMI.
Among female donors only, anti-HCV prevalence increased with the number of pregnancies. Thirty individuals were anti-HCV positive per 100,000 donors (57 of 192,518) among nulligravida women, 57 were positive per 100,000 donors (27 of 47,523) among women with 1 pregnancy, 71 were positive per 100,000 donors (122 of 171,795) among women with 2-4 pregnancies, and 144 per 100,000 (29 of 20,072) in women with у5 pregnancies. In a separate multivariable model with female donors only and including previous transfusion and race/ethnicity along with age, BMI, educational attainment, blood center, and first-time versus repeat donor status, women with multiple pregnancies were significantly more likely to be anti-HCV positive (aOR for 1 pregnancy, 1.3 [95% CI, 0.8-2.1]; aOR for 2-4 pregnancies, 1.6 [95% CI, 1.1-2.4]; aOR for у5 pregnancies, 3.2 [95% CI, 1.9-5.5]; all vs nulligravida women). Country of birth and blood donation procedure were eliminated from the final model because of a lack of statistical significance. Further analyses excluding repeat donors did not substantially change the results reported above.
We next evaluated associations with HCV RNA status among anti-HCV-positive donors (Table 2) . A total of 516 anti-HCVpositive donors had HCV RNA detected, and 179 did not; an additional 24 donors with incident HCV infection (HCV RNA positive but anti-HCV negative) were excluded from further analysis. HCV RNA-negative status was less likely to be detected among donors of black race/ethnicity. However, HCV RNAnegative status was positively associated with greater than high school education, obesity (defined as a BMI 130), and donation at the Georgia blood center. Female sex was not significantly associated with HCV RNA status (aOR, 1.09; 95% CI, 0.74-1.60), but it and other covariates were retained in the model because of prior reports in the literature and/or concern regarding potential confounding factors. Further analyses excluding repeat donors did not substantially change the results reported above.
Because of the above-noted inverse associations of BMI with anti-HCV and HCV RNA positivity, a graph of the frequency distribution of BMI according to anti-HCV and HCV RNA status is shown in Figure 2 . It shows that the entire distribution of BMI is shifted significantly to the right for anti-HCV-positive, HCV RNA-negative donors, compared with both anti-HCV-positive, HCV RNA-positive donors and anti-HCV-negative, HCV RNA-negative donors ( , by ANOVA). P p .008 Anti-HCV-positive, HCV RNA-negative donors are both less likely to be thin and more likely to be overweight or obese than are the other 2 groups.
DISCUSSION
Compared with results from a decade and a half earlier, this study provides additional evidence that anti-HCV prevalence is decreasing among US blood donors, most likely because of culling of seropositive individuals, as well as because of a birth cohort effect. In addition, we describe new associations of anti-HCV prevalence with increasing number of pregnancies among women and with lower BMI among all donors. Finally, HCV RNA-negative status was less likely to be observed among black donors and was more likely to be observed among better educated and obese donors.
The decrease in HCV prevalence in the current analysis, compared with prevalence reported in a similar study for 1992-1993 [4] , is consistent with that seen in other studies of blood donors in the United States and Canada [5, 6, 9] . Over this time, there has been little if any change in donor eligibility criteria. We and others have previously proposed a birth cohort effect for HCV infection among North American blood donors as explaining decreasing prevalence, because donors in the birth cohort at highest risk for HCV infection (those born from the late 1940s through the early 1960s), who have the highest lifetime prevalence of injection drug use [10] , are progressively less represented among active blood donors [4, 6, 9] . The current data, which shows lower age-specific prevalence in all age groups together with a shift in the maximum prevalence to donors who are a decade older, compared with the 1992-1993 data, supports the birth cohort hypothesis, as well as culling of seropositive donors since the introduction of HCV testing in the early 1990s. Similar indications of a birth cohort effect may be seen in US and Japanese general population data [3, 11, 12] . Confirmation of a birth cohort effect is important, because it implies that HCV prevalence in the United States will likely continue to decrease over upcoming decades. The generation born in the late 1940s through the early 1960s will likely manifest the peak incidence of HCV disease outcomes of cirrhosis and hepatocellular carcinoma, with decreasing rates in subsequent generations. Our finding of an association of HCV prevalence with increasing gravidity is novel and of potential public health concern if substantiated by other studies. In favor of the validity of this association is the apparent dose effect with increasing number of pregnancies and its persistence despite adjustment for potential confounding by age, previous transfusion history, race/ethnicity, and education. In light of the weight of evidence against sexual intercourse as a major transmission route of HCV, we do not believe the pregnancy association is a surrogate for sexual transmission [13] . Antenatal care and childbirth are accompanied by medical injections, instrumentation, and a high proportion of cesarian births that could be opportunities for iatrogenic transmission of HCV. Women in our study could also have received transfusions during surgical procedures or while under anesthesia without remembering the event. The hypothesis of iatrogenic exposure is supported by the findings of a case control study of HCV infection among pregnant women in Karachi, Pakistan, which found aORs of 1.25 for 3-4 pregnancies and 1.99 for у5 pregnancies. Those authors concluded that iatrogenic exposures during delivery could be the source of infection [14] .
We could find no published US studies to suggest iatrogenic transmission in the obstetric setting, although a large outbreak of HCV infection has recently been attributed to unsafe injection practices at a Las Vegas endoscopy clinic [15] . A review article counted 33 outbreaks in nonhospital health care settings in the past decade: 12 in outpatient clinics, 6 in hemodialysis centers, and 15 in long-term care facilities, resulting in 448 persons acquiring HBV or HCV infection [16] . Thus, the hypothesis of a low-level iatrogenic risk may be plausible and ought to be examined by other studies. Finally, in this crosssectional study, we cannot rule out residual confounding, perhaps by age or socioeconomic status, as contributing to the observed association.
Our analysis of HCV nucleic acid status found that presumptive clearance of HCV RNA was less likely in black subjects and more likely in those with higher educational status and obesity; no statistically significant association was found between the sexes in the multivariable analysis. The association with black race/ethnicity is consistent with a number of reports in the literature and may be attributable to genetic differences in human leukocyte antigen type or interleukin 18 promoter polymorphism [1, 17, 18] . Polymorphism in the IL28b gene has recently been proposed as a major determinant of racial differences in both treatment response and spontaneous clearance of HCV viremia [19] [20] [21] [22] . The association of HCV clearance with higher educational status was not found in the previous cross-sectional analysis among blood donors [23] . Better access to health care and antiviral treatment among donors with higher socioeconomic status seems unlikely to explain this effect, because most donors were presumably unaware of their HCV status at the time of donation. Our lack of an association of female sex with HCV clearance adds to a divided literature on this topic. Several studies with and without adjustment for potential confounding factors have found that anti-HCV-positive women are more likely to be HCV RNA negative than are their male counterparts [24] [25] [26] [27] , and a prospective study involving young injection drug users observed a higher incidence of clearance among females subjects [28] . However, 3 other studies that included subjects who were US injection drug users, US blood donors, and members of the Italian general population found no significant association of HCV clearance with sex [1, 5, 29, 30] . Because the latter studies generally showed a reduction in odds ratios from univariate to multivariable analysis, it is conceivable that observed associations with sex may be confounded by route of infection or risk group. In addition, the disappearance of anti-HCV, which occurs slowly after resolution of viremia, could lead to differential underestimation of "ever infected" status in cross-sectional studies.
Another novel result of the study is that donors with higher BMI were less likely to have anti-HCV, and among those who had results positive for anti-HCV, those with higher BMI were less likely to test positive for HCV RNA. These findings were somewhat counterintuitive, because the literature implies that chronic infection with HCV may induce a "metabolic syndrome" that includes insulin intolerance and hepatic steatosis [31] . Similarly, patients with HCV infection who are also obese tend to have a higher risk of progression to high-grade fibrosis [32] , perhaps because of increased inflammatory markers observed in patients who are both HCV positive and obese [33, 34] . Obesity is also a risk factor for hepatocellular carcinoma, both with and without HCV infection [35] . On the other hand, a study that specifically excluded obese subjects and those with hepatic steatosis found no effect of HCV infection on insulin resistance [36] . A recent large population-based study in Taiwan, which had findings that were perhaps most similar to our own results, found that anti-HCV positive subjects tended to have lower levels of both cholesterol and triglycerides [37] . Perhaps the key to reconciling these conflicting observations is to separate studies that involve generally healthy populations, such as blood donors, for whom obesity may have a protective effect against HCV infection, from studies involving patients with liver disease, for whom obesity and HCV infection may represent co-morbidities. One study suggested an underlying genetic explanation for these observations, finding that lowdensity lipoprotein receptor polymorphisms may modulate immune response to HCV [38] . Alternatively, an inflammatory state including macrophage infiltration of fat pads and increased production of interleukin 6 and tumor necrosis factor a has recently been linked to obesity and could contribute to the resolution of HCV infection [39, 40] .
Finally, a significantly higher prevalence of HCV clearance at one of the blood centers was a puzzling result. One hypothesis is that this was attributable to differences in HCV genotype. Higher prevalences of the anti-HCV-positive, HCV RNA-negative state have been reported from countries with genotypes other than type 1 [41, 42] . On the other hand, younger injection drug users in San Francisco, California, had a higher ratio of HCV genotype 3 to genotype 1 than did older injection drug users, but the incidence of HCV clearance did not differ by genotype [28] . Blood donors in the southern United States had the highest incidence of new, anti-HCV-negative, HCV RNApositive HCV infections but did not show more non-type 1 HCV genotypes [43] . This suggests another possible explanation for higher proportions of HCV RNA-negative status in Georgia. Most HCV RNA clearance occurs within the first year of infection [28] and may be followed by the disappearance of anti-HCV over a period of several years [44] . Therefore, a higher incidence of new HCV infections at our Georgia center during the time frame of the study could lead to oversampling of resolving infections in individuals who had lost HCV RNA but had not yet lost anti-HCV, compared with a center with lower incidence, where most infections would be in individuals with long-term HCV RNA positivity.
Strengths of the current study include its large size and representation of generally healthy blood donors from several blood centers across the United States. All anti-HCV and HCV RNA testing was performed in parallel and with state-of-theart assays under the rigorous quality control typical of blood center laboratories. Weaknesses include the cross-sectional design, which does not allow true determination of cause and effect, and the possibility of residual confounding of reported associations by measured and unmeasured variables. Although blood center HCV RNA testing performed on individual samples is generally more sensitive than assays used in the clinic [45] , there may be some misclassification of HCV RNA status because of testing in pools of 16 or 24 instead of testing undiluted specimens, although this effect has been shown to be small [46, 47] . Finally, although we believe blood donors are more comparable to the general population than are hospital or clinic patients with HCV infection, conclusions derived from blood donors may not be directly applicable to the general population or to other patients because of selection for better health.
In conclusion, this study provides additional evidence that HCV infection prevalence has decreased substantially among blood donors since 1993, which is consistent with culling of seropositive donors and a birth cohort effect. We found a novel association between HCV infection prevalence and gravidity that will be important to replicate in other US studies because of the public health implications regarding potential iatrogenic transmission in the obstetric setting. Finally, our intriguing results regarding an inverse association of obesity with both HCV infection and viremia may influence the direction of future research on the genetics and metabolic effects of chronic HCV infection, particularly among healthier HCV carriers, as opposed to those with preexisting liver disease. 
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